Dr. David Fajgenbaum

where they are actually funding a lot of the work that we're doing.

And we're finding new uses for medicines that will end up saving money to the healthcare system without actually creating these sort of incentives that maybe aren't aligned.

How big is your team?

We're about 50 people.

50 people?

Yeah.

Is that enough?

I mean, I think that when you think about the world we're in, which is we got 4,000 FDA-approved drugs, and they're approved for about 4,000 diseases, but there's 14,000 more diseases that don't have any approved drugs.

That's a crazy stat, right, Sean?

Yeah.

there's a huge opportunity to match these 4,000 drugs to these 14,000 diseases that, yeah, a 15-member team's not going to be able to do.

So I think that at some point, we're going to need an effort, whether it's ours or in others, that's as big as the Pfizer's and the Merck's of the world that are doing the non-profitable drug development.

I mean, we joke that every cure

is it's a nonprofit drug company, basically.

We're just looking for the nonprofit stuff to help people.

We don't care what the drug was made for.

We don't care how common the disease is.

We just want to relieve suffering with the drugs we already have.

But we joke that we're both the biggest drug company of all time because we'll use any drug out there that can help people.

But we're also the smallest drug company because we don't own any drugs.